J&J revenue misses on lower-than-expected pharmaceutical sales

Apr 18, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital

(Reuters) – Johnson & Johnson, which is in the process of completing its $30 billion acquisition of Swiss biotech Actelion, reported on Tuesday quarterly revenue that missed analysts’ estimates, hurt by lower demand for its pharmaceutical products.